Loading stock data…
Loading stock data…
US$2.15
Get one email when HIND crosses your level. Checked every 15 minutes during market hours.
▼ -0.04 (-1.83%)down today
USD · data via Finnhub · delayed/cached up to 1–5 min
Get an AI-written, balanced deep-dive — performance, valuation, technicals, and the bull vs. bear case. Sign in to get started.
RSI (14-day)
46.7
NeutralAbove 70 can signal overbought; below 30, oversold.
MACD
0.01
Bearish momentumMACD below its signal line (0.01).
50-day average
2.17
Price belowShort-term trend reference.
200-day average
3.26
Price belowLong-term trend reference.
Daily values · indicators are descriptive, not trading advice
Healthcare · Biotechnology
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop i…
www.vyometx.com2 strong buy · 5 buy · 1 hold · 0 sell · 0 strong sell (8 analysts, 2026-07-01)
2 strong buy · 5 buy · 1 hold · 0 sell · 0 strong sell (8 analysts, 2026-06-01)
2 strong buy · 4 buy · 1 hold · 0 sell · 0 strong sell (7 analysts, 2026-05-01)
2 strong buy · 4 buy · 1 hold · 0 sell · 0 strong sell (7 analysts, 2026-04-01)
| Quarter | Estimate | Actual | Result |
|---|---|---|---|
| 2026-05-05 | 2.88 | 3.3 | ✓ Beat |
| 2026-01-23 | 1.61 | 1.87 | ✓ Beat |
| 2025-11-14 | -0.11 | -3.12 | ✗ Miss |
Companies in the same industry, via Finnhub